Interestingly, modulating the lipid pathway, and specifically SP, has been shown to have positive effects in vitro on CMT1A rodent cultured neurons.67 Moreover, changes in SP metabolism have been discovered to be not only limited to the myelin, but can also be found in the biological fluids of CMT1A patients, suggesting a systemic metabolic dysfunction.67 This evidence concerns the gene TFF2 and Charcot-Marie-Tooth disease type 1A.